Compare EIG & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIG | NBTX |
|---|---|---|
| Founded | 2000 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.0M | 1.0B |
| IPO Year | 2006 | 2018 |
| Metric | EIG | NBTX |
|---|---|---|
| Price | $41.36 | $48.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | ★ 166.3K | 62.8K |
| Earning Date | 04-29-2026 | 03-31-2026 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $858,700,000.00 | N/A |
| Revenue This Year | N/A | $58.17 |
| Revenue Next Year | $1.26 | N/A |
| P/E Ratio | $79.67 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.73 | $3.64 |
| 52 Week High | $49.91 | $54.74 |
| Indicator | EIG | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.01 | 66.18 |
| Support Level | $41.08 | $20.11 |
| Resistance Level | $43.19 | N/A |
| Average True Range (ATR) | 1.13 | 2.71 |
| MACD | -0.12 | 1.76 |
| Stochastic Oscillator | 53.85 | 71.11 |
Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations, through its wholly owned subsidiaries.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.